Importantly, compound click-1 has limited cytotoxicity issues compared to other benzamide HDAC inhibitors (such as MS-275), but retains its ability to inhibit recombinant HDACs (Table 1) and increase FXN gene expression in FRDA patient cells (Figure 3). Here, FXN is linked to Friedreich ataxia.